Archive
1318 articles, sorted by publication time.
After PARP inhibitors fail, do cancer cells still have vulnerabilities that can be targeted? ORIC-259 aims to weaken tumor survival by degrading CIP2A messenger RNA; a new collaboration will arrange the first human testing of this preclinical concept.
Two new AAV capsids showed better muscle delivery in mice and nonhuman primates, offering research insights into reducing gene therapy doses. But greater vector delivery and lower liver distribution remain a long way from demonstrating patient benefit and safety.
The UK has accepted all 44 recommendations from its commission on medical AI regulation, extending safety assessment to the periods when products are used and updated. Applications have also opened for the third phase of AI Airlock, which will test how to track risks across different clinical settings and ensure safety information reaches healthcare professionals and patients promptly.
A bispecific antibody that directs T cells toward cancer cells improved disease control in a trial involving newly diagnosed diffuse large B-cell lymphoma; whether these interim results translate into longer survival, and how much treatment burden they add, await the full data.
In more than 50 tissue samples measured outside the body, a research model distinguished two types of skin cancer from normal skin with a test accuracy of about 84%. This offers clues for assessment before biopsy, but whether it can reduce unnecessary sampling still needs to be validated in patients.
After switching from placebo to deramiocel, patients experienced 76% less upper limb functional decline than in the previous year. These new data add second-year follow-up findings, but the open-label design and exploratory analyses limit the questions they can answer.
Whether a wound can heal within three weeks is an important indicator in burn care. DeepView will collect images of the head and face, hands, and feet of adults and children to test whether its model can be applied to these areas; AI results will not guide treatment during the study.
PM577a is beginning to be tested in patients, with the aim of correcting a specific ATP7B mutation to restore the liver’s ability to process copper. Whether a single treatment can ease the burden of lifelong medication remains a question for safety and efficacy data to answer.
Assessing infection risk from a throat photograph first requires proving that the entire system is reliable in clinical settings. Light AI will reassess its model, data and image capture methods; there is no new timeline for clinical studies or the FDA submission process.
SwiftSight measures fat distribution, muscle composition and liver fat using a short MRI scan, with SimonMed set to be the first to adopt it. Regulatory clearance and deployment have progressed, but public data on measurement reliability across populations and clinical benefits remain limited.
Bringing ECGs to where symptoms occur is the gap in care HeartBeam aims to fill. Breakthrough Device designation accelerates communication on development and review, but following a 134-patient pilot study, a pivotal trial is still needed to validate the use; the current cleared indications do not include myocardial infarction assessment.
AL050 aims to address two challenges at once: insufficient enzyme activity and delivery to the brain. The global license brings resources for development, but whether it can clear accumulated lipids and thereby slow the disease remains a question for human studies.